Following FDA approval, the World Health Organization expanded its global HIV prevention guidelines to include Gilead Sciences’ twice-yearly cabotegravir injection for pre-exposure prophylaxis. This long-acting injectable form of PrEP represents a significant advancement in HIV prevention strategies, aimed at improving adherence and reducing transmission worldwide.